Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery and development services, has scheduled its fiscal 2025 second quarter financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers:
- Domestic: 1-800-245-3047
- International: 1-203-518-9765
- Conference ID: INOTIV
A live webcast will be available through the Investors section of Inotiv's website, with a replay accessible afterward at ir.inotiv.com/overview/default.aspx.
Inotiv (NASDAQ: NOTV), un'organizzazione di ricerca a contratto specializzata in servizi non clinici e analitici per la scoperta e lo sviluppo di farmaci, ha programmato l'annuncio dei risultati finanziari del secondo trimestre fiscale 2025 per mercoledì 7 maggio 2025, dopo la chiusura dei mercati.
L'azienda terrà una conference call alle 16:30 ora della costa orientale dello stesso giorno per discutere i risultati. I partecipanti potranno collegarsi telefonicamente utilizzando i seguenti numeri:
- Italia (domestico): 1-800-245-3047
- Internazionale: 1-203-518-9765
- ID conferenza: INOTIV
Una diretta streaming sarà disponibile nella sezione Investitori del sito web di Inotiv, con una registrazione accessibile successivamente all'indirizzo ir.inotiv.com/overview/default.aspx.
Inotiv (NASDAQ: NOTV), una organización de investigación por contrato enfocada en servicios no clínicos y analíticos para el descubrimiento y desarrollo de medicamentos, ha programado el anuncio de sus resultados financieros del segundo trimestre fiscal 2025 para el miércoles 7 de mayo de 2025, después del cierre del mercado.
La empresa realizará una llamada en conferencia a las 4:30 p.m., hora del este el mismo día para discutir los resultados. Los participantes pueden unirse por teléfono usando los siguientes números:
- Local: 1-800-245-3047
- Internacional: 1-203-518-9765
- ID de conferencia: INOTIV
Habrá una transmisión en vivo disponible en la sección de Inversores del sitio web de Inotiv, con una repetición accesible posteriormente en ir.inotiv.com/overview/default.aspx.
Inotiv (NASDAQ: NOTV)는 비임상 및 분석적 신약 발견 및 개발 서비스에 중점을 둔 계약 연구 기관으로, 2025 회계연도 2분기 재무 결과 발표를 2025년 5월 7일 수요일 장 마감 후에 예정했습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 결과를 논의하기 위한 컨퍼런스 콜을 진행합니다. 참가자는 다음 번호를 통해 전화로 참여할 수 있습니다:
- 국내: 1-800-245-3047
- 국제: 1-203-518-9765
- 회의 ID: INOTIV
Inotiv 웹사이트의 투자자 섹션을 통해 생중계가 제공되며, 이후 ir.inotiv.com/overview/default.aspx에서 다시보기가 가능합니다.
Inotiv (NASDAQ : NOTV), une organisation de recherche sous contrat spécialisée dans les services non cliniques et analytiques pour la découverte et le développement de médicaments, a programmé l'annonce de ses résultats financiers du deuxième trimestre fiscal 2025 pour le mercredi 7 mai 2025, après la clôture des marchés.
L'entreprise tiendra une conférence téléphonique à 16h30 heure de l'Est le même jour pour discuter des résultats. Les participants peuvent se joindre par téléphone en utilisant les numéros suivants :
- National : 1-800-245-3047
- International : 1-203-518-9765
- ID de la conférence : INOTIV
Un webcast en direct sera disponible dans la section Investisseurs du site web d'Inotiv, avec un replay accessible par la suite à ir.inotiv.com/overview/default.aspx.
Inotiv (NASDAQ: NOTV), eine auf nichtklinische und analytische Wirkstoffforschung und -entwicklung spezialisierte Vertragsforschungsorganisation, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal des Geschäftsjahres 2025 für Mittwoch, den 7. Mai 2025, nach Börsenschluss, geplant.
Das Unternehmen veranstaltet am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz, um die Ergebnisse zu besprechen. Teilnehmer können sich telefonisch unter folgenden Nummern einwählen:
- Inland: 1-800-245-3047
- International: 1-203-518-9765
- Konferenz-ID: INOTIV
Ein Live-Webcast ist im Investor-Bereich der Inotiv-Website verfügbar, mit einer anschließenden Wiederholung unter ir.inotiv.com/overview/default.aspx.
- None.
- None.
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-245-3047 (Domestic)
- 1-203-518-9765 (International)
- INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1712184&tp_key=c93d44f12f
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/overview/default.aspx.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing non-clinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When will Inotiv (NOTV) release its Q2 2025 earnings?
How can investors join Inotiv's Q2 2025 earnings call?
Where can I find the replay of Inotiv's Q2 2025 earnings webcast?
What period does Inotiv's Q2 2025 earnings report cover?
